Related Experiment Video
Updated: May 12, 2026

A Rat Model of Ventricular Fibrillation and Resuscitation by Conventional Closed-chest Technique
Published on: April 26, 2015
Dronedarone and Captisol-enabled amiodarone in an experimental cardiac arrest
Benedict M Glover1, Xudong Hu, Theresa Aves
1Keenan Research Centre in the Li Ka Shing Knowledge Institute of St Michael's Hospital, Toronto, Ontario, Canada.
Objective:
To compare the energy required for defibrillation and postshock outcomes after the administration of dronedarone, amiodarone, and placebo in a porcine model of cardiac arrest.
Methods:
Forty-two pigs were randomized to amiodarone, dronedarone, or control treatments. After induction of ventricular fibrillation, compressions and ventilations were performed for 3 minutes and treatment was administered over 30 seconds. If defibrillation was unsuccessful, cardiopulmonary resuscitation continued and repeated shocks were administered every 2 minutes with continual hemodynamic monitoring for a total duration of 30 minutes.
Results:
The cumulative energy required for defibrillation was 570 ± 422 J for dronedarone, 441 ± 365 J for amiodarone, and 347 ± 281 J for control (P = not significant). Survival at 30 minutes was 1 (7.1%) for dronedarone compared with 11 (78.6%) for control (P = 0.001). Mortality in the dronedarone group was because of refibrillation in 3 (21.4%) cases, atrioventricular block in 1 (7.1%) case, and hypotension not because of bradycardia in 9 (64.3%) cases. Two minutes after successful defibrillation, systolic aortic pressure was lower in dronedarone versus control (86.6 ± 26.9 vs. 110 ± 15.1 mm Hg; P = 0.035).
Conclusions:
The administration of dronedarone resulted in a significant reduction in survival and both systolic aortic and coronary perfusion pressure compared with control.
Related Concept Videos
Cardiopulmonary Resuscitation IV: Pharmacological Management
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Cardiopulmonary Resuscitation III: AED Use
Heart Failure Drugs: Inotropic Agents
Dysrhythmias VI: Management of Dysrhythmias
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers